News Sentiment

ATYR sentiment intelligence

aTyr Pharma, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 40 Balanced news tone 32 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.54 Week of 10 Jul 2026
Weighted tone 40/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

72/100 classification confidence.

Company focus 24

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-8.1% over one week, +23.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

aTyr Pharma submits Phase 3 protocol for lung disease drug

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 72/100 classification
One-week reaction -8.1% Price reacting lower
Trend fit Trend inactive 23.6% over four weeks
Fair value -74.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 4
Neutral 16
Negative 12

Relevance

Why the article matched

Direct first
Direct company coverage 24
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 7
The National Law Review 7
Market source 6
Stock Titan 5
simplywall.st 2
Investing.com 1
Moomoo 1
AD HOC NEWS 1

Event Lens

What the news is about

Classified themes
Earnings 10
Market update 10
Regulatory and legal 7
Analyst action 3
Guidance 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 32
Investing.com Direct company coverage

aTyr Pharma submits Phase 3 protocol for lung disease drug

aTyr Pharma (NASDAQ:ATYR) has submitted a Phase 3 study protocol to the FDA for its drug efzofitimod, targeting chronic pulmonary sarcoidosis with restrictive lung disease. This follows positive subgroup analysis from a previous Phase 3 study and the company expects to use forced

Tone
Positive 72/100
Event
Guidance
Published
15 Jul 2026 12:46
Source
Investing.com
Moomoo Direct company coverage

JonesTrading Maintains ATyr Pharma(ATYR.US) With Hold Rating

JonesTrading has reiterated its Hold rating on ATyr Pharma (ATYR.US). This indicates that the firm advises investors to maintain their current position in the company's stock without recommending buying or selling.

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jul 2026 01:42
Source
Moomoo
Stock Titan Direct company coverage

Federated Hermes (NASDAQ: ATYR) amends 13G, reports 8.51M shares

Federated Hermes, Inc. has filed an amendment on Schedule 13G/A, disclosing beneficial ownership of 8,509,678 shares of aTYR PHARMA INC common stock, which represents 8.68% of the class as of June 30, 2026. The filing includes a Rule 13d-4 disclaimer, stating that Federated Herme

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 11:37
Source
Stock Titan
TradingView Direct company coverage

aTyr Pharma, Inc. Actuals & Estimates (HAM:471A)

This article provides financial actuals and estimates for aTyr Pharma, Inc. (HAM:471A), including income statement, balance sheet, cash flow, and valuation metrics. It also offers analyst forecasts, historical price data, upcoming earnings reports, and key financial figures like

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 09:10
Source
TradingView
AD HOC NEWS Direct company coverage

aTyr Pharma updates its pipeline strategy as LIFE advances clinical programs

aTyr Pharma, a clinical-stage biotechnology company, is updating its pipeline strategy as its LIFE program and other protein-based therapeutic candidates progress through clinical development, targeting immune and inflammatory pathways. The company relies on equity financing, col

Tone
Positive 66/100
Event
Market update
Published
07 Jul 2026 14:33
Source
AD HOC NEWS
The National Law Review Direct company coverage

ATYR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of aTyr Pharma, Inc. to Contact the Firm Today!

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against aTyr Pharma, Inc. (NASDAQ:ATYR) on behalf of investors who purchased securities between January 16, 2025, and September 12, 2025. The lawsuit alleges that aTyr made false and misleading statements regardi

Tone
Negative 14/100
Event
Regulatory and legal
Published
06 Jul 2026 11:39
Source
The National Law Review
Stock Titan Direct company coverage

If You Invested $1,000 in Atyr Pharma Inc (ATYR)

This article analyzes the historical performance of Atyr Pharma Inc (ATYR) stock, demonstrating the significant losses an investment of $1,000 would have incurred over 1, 5, and 10 years compared to the S&P 500. It also provides a detailed overview of Atyr Pharma, including its f

Tone
Negative 14/100
Event
Market update
Published
04 Jul 2026 22:41
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBIT forward of aTyr Pharma, Inc. – NASDAQ:ATYR

This article provides limited financial information for aTyr Pharma, Inc. (NASDAQ: ATYR) focusing on its enterprise value to EBIT forward. The content is primarily a data placeholder from TradingView, indicating that specific financial figures for this metric are not available or

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 11:39
Source
TradingView
The National Law Review Direct company coverage

Class Action Filed Against aTyr Pharma, Inc. (ATYR) Over Securities Violations - Contact Levi & Korsinsky Today

Levi & Korsinsky, LLP has filed a class action securities lawsuit against aTyr Pharma, Inc. (NASDAQ: ATYR) alleging securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims aTyr made misleading statements about the efficacy of its drug Efzofitimod, pa

Tone
Negative 24/100
Event
Regulatory and legal
Published
30 Jun 2026 10:40
Source
The National Law Review
TradingView Direct company coverage

Price to book forward of aTyr Pharma, Inc. – NASDAQ:ATYR

This article provides access to the "Price to book forward" financial metric for aTyr Pharma, Inc. (NASDAQ: ATYR) on TradingView. It highlights that the market was closed at the time of access and offers no specific financial data within the provided text, instead serving as a po

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 18:41
Source
TradingView
The National Law Review Direct company coverage

Burned by aTyr Pharma, Inc.? Contact Levi & Korsinsky to SueWallSt And Fight Back

Levi & Korsinsky has filed a class action lawsuit against aTyr Pharma, Inc. on behalf of investors who experienced losses due to alleged securities fraud between November 7, 2024, and September 12, 2025. The firm, known for securing significant amounts for aggrieved shareholders,

Tone
Negative 19/100
Event
Regulatory and legal
Published
29 Jun 2026 09:39
Source
The National Law Review
The National Law Review Direct company coverage

Investors SueWallSt Over aTyr Pharma, Inc. Stock Drop - Contact Levi & Korsinsky to Join

A class action lawsuit has been filed against aTyr Pharma, Inc. on behalf of investors who incurred losses due to alleged securities fraud between November 7, 2024, and September 12, 2025. Investors are encouraged to contact Levi & Korsinsky through SueWallSt if they suffered los

Tone
Negative 19/100
Event
Regulatory and legal
Published
29 Jun 2026 09:09
Source
The National Law Review
The National Law Review Direct company coverage

Join Class Action to Recover Losses from aTyr Pharma, Inc. (ATYR)

Levi & Korsinsky LLP has filed a class action lawsuit against aTyr Pharma, Inc. (ATYR) on behalf of investors who suffered losses due to alleged securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims that the company made misleading statements about

Tone
Negative 5/100
Event
Regulatory and legal
Published
28 Jun 2026 18:10
Source
The National Law Review
The National Law Review Direct company coverage

Investors in aTyr Pharma, Inc. (ATYR): Protect Your Rights - Contact Levi & Korsinsky Before December 8, 2025

Levi & Korsinsky LLP is inviting investors in aTyr Pharma, Inc. (NASDAQ: ATYR) to contact them regarding a class action securities lawsuit. The lawsuit seeks to recover losses for shareholders affected by alleged securities fraud between November 7, 2024, and September 12, 2025,

Tone
Negative 14/100
Event
Regulatory and legal
Published
28 Jun 2026 14:10
Source
The National Law Review
The National Law Review Direct company coverage

Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) - Contact Levi & Korsinsky Before December 8, 2025

Levi & Korsinsky LLP has filed a class action securities lawsuit against aTyr Pharma, Inc. (NASDAQ: ATYR) alleging securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims that the company made false and misleading statements regarding the efficacy of

Tone
Negative 28/100
Event
Regulatory and legal
Published
28 Jun 2026 00:40
Source
The National Law Review
TradingView Direct company coverage

aTyr Pharma, Inc. Actuals & Estimates (NASDAQ:ATYR)

This article provides an overview of aTyr Pharma, Inc. (NASDAQ: ATYR) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers frequently asked questions about the company's stock, market capitalization, earnings reports, and vo

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 07:09
Source
TradingView
TradingView Direct company coverage

ATYR Forecast — Price Target — Prediction for 2027

The article provides a forecast for aTyr Pharma, Inc. (ATYR) stock, including a 1-year price target of $2.86 based on analyst estimates. It details the company's current stock price, historical highs and lows, market capitalization, and upcoming earnings report. The piece also su

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 18:40
Source
TradingView
The Globe and Mail Direct company coverage

aTyr Pharma Granted Nasdaq Extension to Regain Compliance

aTyr Pharma has received an extension from Nasdaq until November 30, 2026, to regain compliance with the minimum $1.00 bid price requirement. The company was initially notified on December 4, 2025, and granted an extension on June 3, 2026, to avoid delisting. Analyst sentiment on

Tone
Negative 38/100
Event
Analyst action
Published
10 Jun 2026 13:09
Source
The Globe and Mail
Sahm Direct company coverage

Insider Buyers At aTyr Pharma Likely Disappointed With 19% Slide

Insiders at aTyr Pharma, including Paul Schimmel, bought US$911.8k worth of stock at an average price of US$0.91 over the past year. Despite their confidence, the stock has since slid by 19%, reducing their investment to US$442.1k. While insider ownership stands at 2.5%, the rece

Tone
Negative 39/100
Event
Market update
Published
09 Jun 2026 13:02
Source
Sahm
TradingView Direct company coverage

aTyr Pharma Received Notice of Noncompliance

aTyr Pharma (ATYR) announced on June 3, 2026, that it received a Nasdaq letter granting an additional 180 days, until November 30, 2026, to comply with the $1.00 minimum bid price requirement. The notice does not immediately affect its Nasdaq listing, and the company may consider

Tone
Negative 29/100
Event
Market update
Published
08 Jun 2026 20:38
Source
TradingView